This has implications in cell specific miR (i.e. miR-146a-mimic conjugated to CpG) (54) and molecular gene target applications (TRAF6 inhibitors, etc) for future therapeutic application in autoimmune diseases, that are currently being explored. This evidence concerns the gene TRAF6 and autoimmune disease.